Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Intra-arterial gemcitabine delivered via RenovoCath (TAMP platform) in ongoing Phase III TIGeR-PaC trial for LAPC. Orphan Drug Designation for pancreatic cancer and bile duct cancer. New IIT in cholangiocarcinoma began Q2 2026.
Oxaliplatin (TAMP)
Stage not disclosed · ActiveModality: drug-device combination
Indications
Pancreatic cancer(Stage not disclosed)
Status note Oxaliplatin delivered via RenovoCath under TAMP platform; Orphan Drug Designation granted Q2 2026 for pancreatic cancer.
RenovoCath
Approved · ActiveModality: medical device
Indications
Vessel occlusion (device indication)(Approved)
Status note FDA-cleared for temporary vessel occlusion (arteriography, preoperative occlusion, chemotherapeutic drug infusion). Actively commercialized as standalone device.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.